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Introduction 
HIV/AIDS remains one of the world's most significant public health challenges in low- and 
middle-income countries: about 36.7 million people living with HIV, 2.1 million people 
becoming newly infected, Sub-Saharan Africa being the most affected region with 25.6 
million people living with HIV in 2015 
[1, 2]
. ARVs are not spared from counterfeiting due to 
their substantial high unit costs, long term and sustained demand. Several case reports of 
counterfeit ARVs are published 
[3-5] 
among which the WHO alert in 2003 towards a product 
called 'Ginovir 3D' marketed in Ivory Coast as a triple ARV combination. It was containing 
only one of the three labeled active ingredients and a non-declared other ARV agent 
[3]
. As the 
antiretroviral therapy (ART) constitutes a growing pharmaceutical research field combining 
several ARV medicines to maximally suppress the HIV virus and stop the progression of HIV 
disease, there is need of disposing rapid and efficient analytical methods to serve at different 
stages of drug development to ensure quality, safety and efficacy. Unfortunately this 
pertaining demand is in contrast with few existing monographs dedicated to the analysis of 
multiple ARV combinations including those already marketed. 
Purpose / Goals  
We targeted the development of LC methods that can analyze 18 antiretroviral medicines 
namely abacavir (ABC), didanosine (ddI), efavirenz (EFV), emtricitabine (FTC), indinavir 
(IDV), lamivudine (3TC), lopinavir (LPV), nelfinavir (NFV), nevirapine (NVP), raltegravir 
(RAL), ritonavir (RTV), saquinavir (SQV), stavudine (d4T), tenofovir (TDF), zidovudine 
(ZDV or AZT), atazanavir (ATZ), darunavir (DRV), etravirine (ETV). This group includes 4 
major excipients mostly used in oral suspension formulations: butylated hydroxytoluene 
(BHA), butylated hydroxyanisole (BHT), nipagine (NpG), and nipasol (NpS).  
Materials and Methods 
The methods were developed through design of experiment and design space (DoE/DS) 
methodology 
[6-8]
. Focusing on rapid and affordable aspects, a short column (RP18, 100 mm x 
4.6 mm (ID), 3.5µm (dp)) and low cost organic solvent (methanol) were used in gradient 
mode with 10 mM ammonium dihydrogen carbonate buffer or ammonium formate buffer as 
mobile phase. Prior to the use in routine analyses, one method was validated according to the 
total error approach taking into account the accuracy profile as decision tool 
[9]
.  
Results and Discussion 
The screening method was predicted thanks to Monte Carlo simulations for the analysis of 18 
compounds and 4 excipients above listed. The column temperature optimized at 35°C and 
gradient time at 21.3 min allowed monitoring these compounds at 210 nm. Another prediction 
was carried out for fixed dose combination of EFV/FTC/TDF. The validation results for that 
combination in tablet formulations was satisfying in terms of selectivity/specificity, trueness, 
precision, accuracy, linearity and dozing range. Two samples coded A and B were analyzed 






Claimed content  
(Found content in %) 
FTC 
Claimed content  
(Found content in %) 
TDF 
Claimed content  
(Found content in %) 
Code A 
  
600 mg 200 mg 300 mg 
100.3 ± 1.04 % 80.2 ± 0.78 % 84.8 ± 1.17 % 
Code B 
  
- 200 mg 300 mg 
- 93.1 ± 1.74 % 91.5 ± 1.40 % 
 
Conclusion 
We were able to separate 18 ARV compounds and 4 major preservatives thanks to DoE-DS. 
The method was satisfying to quantify three ARV in tablet samples. The DoE/DS database 
can serve in the prediction of other optimal conditions for any fixed-dose combination.  
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